Flurpiridaz, using an F-18 label with a 109-minute half-life, enables PET imaging with unit doses, making it more economical and accessible. It offers improved diagnostic precision over SPECT, supports treadmill stress tests for more accurate heart function assessment, and can detect microvascular disease. This could significantly boost PET adoption in nuclear cardiology.